nitrendipine has been researched along with Nephrosclerosis in 2 studies
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.
Nephrosclerosis: Hardening of the KIDNEY due to infiltration by fibrous connective tissue (FIBROSIS), usually caused by renovascular diseases or chronic HYPERTENSION. Nephrosclerosis leads to renal ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension." | 7.68 | Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. ( Helmchen, U; Schoeppe, W; Schwietzer, G; Troschau, G; Wenzel, UO, 1992) |
| "The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension." | 3.68 | Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. ( Helmchen, U; Schoeppe, W; Schwietzer, G; Troschau, G; Wenzel, UO, 1992) |
| "Arterial hypertension is the most common chronic medical condition requiring office visits to physicians and is a major contributing factor to the development of myocardial infarction and stroke." | 2.40 | How should we treat hypertensive women with cardiac and renal impairment? ( Ruilope, LM; Suarez, C, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ruilope, LM | 1 |
| Suarez, C | 1 |
| Wenzel, UO | 1 |
| Troschau, G | 1 |
| Schoeppe, W | 1 |
| Helmchen, U | 1 |
| Schwietzer, G | 1 |
1 review available for nitrendipine and Nephrosclerosis
| Article | Year |
|---|---|
How should we treat hypertensive women with cardiac and renal impairment?
Topics: Adrenergic beta-Antagonists; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diuretics; | 1997 |
1 other study available for nitrendipine and Nephrosclerosis
| Article | Year |
|---|---|
Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.
Topics: Albuminuria; Animals; Antihypertensive Agents; Blood Pressure; Drug Combinations; Enalapril; Hemodyn | 1992 |